Insulin resistance (IR) in patients with metabolic syndrome (MetS), who are at high cardiovascular risk, is associated with impaired insulin signaling via the insulin receptor substrate-2- (Irs2-) AKT2 pathway in mononuclear leukocytes (MLs) [5]. Here, IRS2 is linked to metabolic syndrome.